Stop Immunology-ing Cardiology
Atherosclerosis may be inflammatory, but immunosuppression is not going to fix it
Autoimmune Drug Development Report
What's coming, what just landed, and where the industry is getting it wrong — a rheumatologist's take on autoimmune drug development.
Live Last read · last published · next check
Latest episodes
EBR Journal Club: Dapirolizumab Pegol in SLE (PHOENYCS GO)
A companion to the Evidence Based Rheumatology podcast Episode 138
NEJM Retracts Avacopan
An unprecedented retraction reveals cracks in the very foundations of drug development
EBR Journal Club: Obexelimab in IgG4-Related Disease (INDIGO)
A companion to the Evidence Based Rheumatology podcast, Episode 137
EBR Journal Club: Secukinumab in Polymyalgia Rheumatica (REPLENISH)
A companion to the Evidence Based Rheumatology podcast Episode 136
“Peptides,” BPC-157, and the Mainlining of Pseudoscientific Nonsense
30 years of rat-research and an avalanche of un-earned hype is coming to your clinic
The (sc)Pen is Mightier Than the (iv)Cord
SC anifrolumab hits the market
Re-Adjudicating Avacopan
The FDA names names and moves to remove avacopan from the market
EBR Journal Club: Ixekizumab + Tirzepatide in Psoriatic Arthritis (TOGETHER-PsA)
A companion to the Evidence Based Rheumatology podcast episode 135
The CAR-T Landscape in Autoimmune Disease
Pipeline Monitor #2: AKA trying to get a handle on all this CAR-T madness
EBR Journal Club: Brepocitinib in Dermatomyositis (VALOR)
A companion to the Evidence Based Rheumatology podcast, Episode #134
Critical Commentary: Run Fewer Phase 2 Trials
Our most expensive ritual in drug development is mostly FDA-mandated(ish) theater.
Regulatory Breakdown: Nerandomilast for Progressive Pulmonary Fibrosis
The surprising mortality benefit for Nerandomilast (Jascayd) in progressive pulmonary fibrosis
EBR Journal Club: Obinutuzumab in SLE (ALLEGORY)
A companion to the Evidence Based Rheumatology podcast, Episode #133
Regulatory Breakdown: Deucravacitinib (Sotyktu) for Psoriatic Arthritis
The Sixth Mechanism Arrives. Does Anyone Need It?
Critical Commentary: One Trial to Rule Them All
Unfortunately, there are no solutions in drug development, only trade offs
Pipeline Monitor: Avacopan Under Fire & B Cells are Having a Moment
But emerging indications for JAK/TYKs may be the story that lasts
Welcome to the Autoimmune Drug Development Report
What's coming, what just landed, and where the industry is getting it wrong - a rheumatologist's take on autoimmune drug development.